Malin stock
Price history
−27.71% over the period1 year: from €8.30 (November 13, 2025) to €6.00 (November 13, 2026), −27.71%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | €6.00 |
| October 30, 2026 | €5.95 |
| September 30, 2026 | €7.00 |
| August 31, 2026 | €7.00 |
| July 31, 2026 | €7.10 |
| June 30, 2026 | €7.45 |
| May 29, 2026 | €7.75 |
| April 30, 2026 | €7.95 |
| March 31, 2026 | €7.70 |
| February 27, 2026 | €7.60 |
| January 30, 2026 | €8.00 |
| December 31, 2025 | €7.70 |
| November 28, 2025 | €7.85 |
| November 13, 2025 | €8.30 |
At a glance
The company
Investment company focusing on life sciences and healthcare companies across oncology, immunology, and genetic diseases
Latest results
Quarter to December 31, 2025 · EPS -€0.05
Next event
TickerLandia's take on Malin
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−35.48% from the 52-week high
Analysts · 1 analyst
Average target€15.50+158.33% vs. price
Buy 1 · Hold 0 · Sell 0
TickerLandia Fingerprint: Malin
Compared with similar companies: very low profitability and very weak momentum.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Profitabilityvery low6
How much it earns on revenue and capital.
Metric Value Position in group ROE −6.0% 6 ROA −1.4% 6 Operating margin 0.0% 9 Gross margin 0.0% 1 Net margin 0.0% 9 Financial strengthaverage50
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 16.1 99 Interest coverage −13.5 1 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak7
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −27.71% 6 Distance from 200-day average −17.68% 7 Riskaverage51
How much the price swings.
Metric Value Position in group Volatility (60 days) 24.2% 38 Maximum drawdown (12 months) 28.3% 65
3 dimensions without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Malin is cheaper than similar companies
Malin's Price/book: 0.67, −77% against the median of a group of 11 similar companies (2.91).
Compared with 11 similar companies
| Metric | Malin | Position in the group | Band |
|---|---|---|---|
| Operating margin | 0.0% | Low | |
| ROE | -6.0% | Low | |
| Price/book | 0.67 | Low | |
| Net margin | 0.0% | Low | |
| Gross margin | 0.0% | Low |
Grey band: the middle half of the group; tick: the median; dot: Malin. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Net income
-€200K
Latest quarter · Q4 2025
Numbers and valuation
Full valuation- Market cap
- €25.96M
- EPS
- €0.00
- Volume
- 10
- Daily trading
- €2.18K
- Dividend yield
- 0.00%
How Malin is changing
All resultsShares outstanding down 83.8% in 5 years
Profitable in 2 of 5 fiscal years
Returns
Malin returns
€1,000 invested in Malin 5 years ago, on November 15, 2021, would be worth €896 today: −10.45% in total, −2.19% per year. This is the price return only: dividends are excluded.
| Period | Malin | €1,000 becomes |
|---|---|---|
| 1 month | −13.67% | €863 |
| 6 months | −25.00% | €750 |
| Year to date | −22.08% | €779 |
| 1 year | −27.71% | €723 |
| 3 years | +50.00% | €1,500 |
| 5 years | −10.45% | €896 |
| 10 years | −50.12% | €499 |
Price only, without dividends. Calculate your investment
The chart in detail
Malin: technical analysis
Malin is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 61.0% below its all-time closing high (€15.36, June 30, 2016).
- Trend
- Downward
- RSI (14 sessions)
- 15
- Below 30: a strong fall in a short time
- vs 200-session average
- −17.68%
Active signals
RSI below 30: the stock has fallen a lot in a short time.
since October 22, 2026
Support and resistance
Price areas where Malin has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€7.12+18.59%13 touches, last on August 4, 2026
- Resistance€7.00+16.59%65 touches, last on October 21, 2026
- Resistance€6.80+13.33%3 touches, last on September 21, 2026
- Last price€6.00
- Support€5.95−0.83%8 touches, last on November 6, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 24.2%
- Largest fall in the last year
- −28.31%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Malin: seasonality
Average monthly price change over 13 years
Over the last 13 years, the strongest month for Malin has been November: +7.84% on average, positive in 9 years out of 12. The weakest has been October: −5.05% on average, positive in 2 years out of 13.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.88% | +4.30% | 8 of 12 |
| February | +1.02% | −1.23% | 3 of 12 |
| March | −2.21% | +0.66% | 6 of 12 |
| April | −3.02% | −1.34% | 5 of 13 |
| May | −0.71% | 0.00% | 5 of 13 |
| June | +3.23% | 0.00% | 6 of 13 |
| July | −1.88% | 0.00% | 5 of 13 |
| August | −4.18% | −0.71% | 4 of 13 |
| September | +3.60% | −0.87% | 2 of 13 |
| October | −5.05% | −6.96% | 2 of 13 |
| November | +7.84% | +6.01% | 9 of 12 |
| December | +2.17% | −0.41% | 5 of 12 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Malin and its competitors
Europe and North America are the markets in which Malin Corporation plc operates as an investment company, together with its subsidiaries. The group invests in life sciences and healthcare companies, with a focus on therapeutic areas such as oncology, immunology and genetic diseases. Its holdings are therefore tied to businesses working in these fields across the two regions.
- Headquarters
- Dublin, Ireland
- Employees
- 2
- Founded
- 2014
- Chief executive
- Fiona Dunlevy
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| MalinMLC | $28.69M | 0.0% | — | −25.00% |
| EvotecEVT | $582.49M | -18.0% | — | −35.51% |
| PharmaNutraPHN | $880.46M | 21.7% | 35.0 | −6.12% |
| Faes FarmaFAE | $1.74B | 13.0% | 18.7 | +10.55% |
| FagronFAGR | $1.96B | 14.3% | 19.4 | −0.21% |
| AlmirallALM | $2.57B | 13.3% | 32.4 | −5.83% |
Same industry or related industries, similar size. Compare Malin with its competitors · Full profile
